A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in methicillin-resistant staphylococcus aureus (MRSA) infection; an open-label, non-randomized study

A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in methicillin-resistant staphylococcus aureus (MRSA) infection; an open-label, non-randomized study - A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in MRSA infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004322

Enrollment

Registered

2010-10-04

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA infection

Interventions

All patients receive a dose of 600 mg linezolid every 12h orally or intravenously, and their blood samples are assayed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age, 20 years or higher 2) MRSA infections, including suspicions 3) Inpatients and outpatients in our hospital 4) Prescribed blood sampling were available 5) gave their or their relatives' written informed consent

Exclusion criteria

Exclusion criteria: 1) history of hypersensitivity to ZYVOX 2) pregnancy, parturition or lactation 3) other situation that doctor decides

Design outcomes

Primary

Measure	Time frame
A relationship between linezolid-induced myelosuppression and serum linezolid concentrations	—

Secondary

Measure	Time frame
Blood concentration-time profile of major metabolites in patients Urinary excretion amounts of linezolid and major metabolites in patients	—

Countries

Japan

Contacts

Public ContactYoshimichi Sai

Kanazawa University Hospital Department of Pharmacy

sai-ys@staff.kanazawa-u.ac.jp076-265-2046

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026